Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
35 results
D1.242 - Early-Life Dietary Diversity and the Risk of Atopic Dermatitis: A Nationwide Population-Based Cohort Study
D1.244 - Clinical heterogeneity of pediatric atopic dermatitis: latent class analysis
D1.241 - Clinical and Immunological Phenotypes of Alopecia Areata in Children with Atopic Dermatitis
D1.236 - The role of tissue resident memory cells in immunodermatological disorders: A Systematic Review
D1.237 - Mental Health and Neurodevelopmental Comorbidities in Pediatric Atopic Dermatitis: A Retrospective Study and Literature-Based Perspective
D1.238 - Natural history of early onset atopic dermatitis and risk factors for persistency using Korean National Health Service data
D1.239 - Are Maternal Epidermal Lipid Profiles Associated with Atopic Dermatitis Development in Early Childhood?
D1.240 - ATH-409, a selective and covalent ITK inhibitor, protects against atopic dermatitis in preclinical models
D1.245 - The role of advanced glycation end products as facilitating factors in the pathogenesis of atopic dermatitis in pediatric patients
D1.246 - Characterization of Unmet Need for Targeted Precision Medication in Atopic Dermatitis Due to Inadequate Response or Adverse Reactions to Dupilumab
D1.247 - Changes in the sensitization profile in allergic contact dermatitis: comparison between two populations separated by 10 years in a secondary hospital in northern Portugal
D1.248 - Intersection of Autoimmune Mechanisms: Coexistence of Celiac Disease and Chronic Urticaria
D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)
D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety
D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A
D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody
D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series
D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria
D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis
D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download